[Form 4] GeneDx Holdings Corp. Insider Trading Activity
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Feeley Kevin
Role
CHIEF FINANCIAL OFFICER
Sold
5,278 shs ($491K)
Approx. gross sale proceeds
$491K
Approx. exercise cost
$41K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) | 1,245 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 1,245 | $32.67 | $41K |
| Sale | Class A Common Stock | 5,278 | $93.00 | $491K |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 6,228 contracts (Direct);
Class A Common Stock — 3,392 shares (Direct)
Footnotes (3)
- F1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 21, 2024.
- F2. Following the reported sales and option exercise, in addition to the 3,392 shares of Class A common stock and the option to purchase up to 6,228 shares of Class A common stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned restricted stock units ("RSUs") representing contingent rights to receive up to an aggregate of 135,762 shares of Class A common stock and additional options to purchase up to an aggregate of 20,924 shares of Class A common stock, which RSUs and options vest according to their respective terms.
- F3. 6.25% vest in quarterly installments over the 4-year period commencing on December 1, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.